Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

DARK SECRETS: 21 | Rare Historical Photos

What’s the UK’s booster policy ahead of a feared autumn Covid wave?

Tweaked vaccines to tackle Omicron are in trials as JCVI finalises advice for vulnerable groups

The Guardian - UK

New Moderna 'super-booster' jab to target Wuhan and Omicron strains 'coming in Autumn'

The jab, known as “214”, is bivalent, which means it helps build immunity to both the original Wuhan strain and the Omicron variants

Daily Mirror

Covid: Urgent call to update vaccines to target variants as cases rise to near-record levels

The case is growing to tweak the jabs to target more tranmissible Omicron variants, experts say

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

What Are Whales Doing With Moderna

A whale with a lot of money to spend has taken a noticeably bullish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 19 strange trades.

Benzinga

FDA says COVID boosters for the fall must target newer omicron types

With immunity waning and the super-contagious omicron family of variants getting better at dodging protection, the Food and Drug Administration decided boosters intended for fall needed an update.

WEKU

Tweaked COVID boosters in US must target newer omicron types

U.S. regulators are telling COVID-19 vaccine makers to tweak any booster doses intended for fall so they protect against the newest omicron relatives

The Independent UK

COVID vaccination reboot coming this fall to add tweaks for new coronavirus variants

The FDA will have to decide the exact recipe. But expect a combination shot that adds protection against omicron or some of its newer relatives to the original vaccine.

Chicago Sun-Times

Read news from The Economist, FT, and more,
with one subscription

Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'

The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news, announced Tuesday, June 28, could have a big impact on the share prices of vaccine makers.

Benzinga

Detroit makes COVID vaccines available for children 6 months to 5 years

DETROIT — The city is providing COVID vaccines from Pfizer and Moderna for children ages 6 months up to 5 years of age, following emergency authorization from the federal Food and Drug Administration and approval from the state health department.

Tribune News Service

COVID shots should get omicron-targeted update, FDA advisers say

COVID-19 shots from Pfizer Inc. and Moderna Inc. should be updated to include components that target the highly transmissible omicron variant, the version of the virus that causes most of the world’s cases, U.S. regulatory advisers said.

Tribune News Service

Canada needs to invest more money into science innovation to help prevent the next global crisis

Canada has lagged behind its peer nations in innovation for decades. Currently, Canada is ranked 11th out of the 16 similarly developed countries assessed. While our “C” grade is a moderate improvement over our previous “D” grade, innovation still remains a barrier to high-quality job creation and economic prosperity in…

The Conversation

US grapples with whether to modify COVID vaccine for fall

U.S. health authorities are facing a critical decision: whether to offer new COVID-19 booster shots this fall that are modified to better match the latest changes of the shape-shifting coronavirus

The Independent UK

What Are Whales Doing With Moderna

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 13 strange trades.

Benzinga

Walmart And 3 Other Stocks Insiders Are Selling

US stock futures traded slightly higher this morning on Monday after recording sharp gains in the previous session. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

Should you get a COVID-19 booster shot now or wait until fall? Two immunologists help weigh the options

While COVID-19 vaccines continue to be highly effective at preventing hospitalization and death, it has become clear that the protection offered by the current vaccines wanes over time. This necessitates the use of booster shots that are safe and effective in enhancing the immune response against the virus and extending…

The Independent UK

UK among worst offenders in G7 vaccine supply failures ‘which led to 600,000 preventable deaths’

With days left until Britain reaches the deadline to fulfil its 100 million dose pledge, only 39 per cent have actually been delivered

WEKU

Pfizer says its tweaked COVID-19 shots boost protection against the omicron variant

Pfizer said that tweaking its vaccine to better target the omicron variant is safe and works — just days before regulators debate whether to offer Americans updated booster shots this fall.

The Independent UK

Pfizer says tweaked COVID-19 shots boost omicron protection

Pfizer says tweaking its COVID-19 vaccine to better target the omicron variant is safe and boosts protection

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Moderna COVID-19 shots now an option for older kids in US

There is now a second COVID-19 option for kids ages 6 to 17 in the U.S. The Centers for Disease Control and Prevention on Friday announced it is recommending Moderna shots as an option for school-age kids and teens

Benzinga

Moderna Has Multi-Billion-Dollar Opportunity Outside Of COVID-19 Vaccines, Analyst Says

Moderna, Inc. (NASDAQ: MRNA) rose to prominence with its messenger RNA-based COVID-19 vaccine.

The Independent UK

Experts endorse Moderna COVID-19 shots for kids ages 6 to 17

An expert panel backed a second COVID-19 vaccine option for kids ages 6 to 17

The Philadelphia Inquirer

Research behind COVID vaccines reaps close to $1 billion in royalties for Penn

PHILADELPHIA — The University of Pennsylvania has reaped extraordinary financial gain from COVID-19 vaccines — approaching $1 billion since the beginning of last year — thanks to patents on a process Penn researchers developed more than 15 years ago.

Daily Record

Moderna confirms two-in-one Covid and flu jab in the works as testing under way

Scientists have developed an alternative to the current separate inoculations with the trial already under

Benzinga

This Is What Whales Are Betting On Moderna

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Daily Mirror

Young adults and children should get Covid booster jabs this autumn, vaccine chiefs warn

The announcement comes after the UK is seeing a spike in Covid-19 cases and follows a trial of Moderna's new vaccine designed to tackle the more contagious sub-variants of Omicron

1 … 20 21 22 23

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

337 stories

Centers for Disease Control and Prevention

314 stories

Pfizer Inc

313 stories

Imperial College London

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.